Sequenom - 500 Beiträge pro Seite

[Helmut_Krumme]

Hi
Sequenom ist heute massiv und unter riesigen Umsätzen
ausgebrochen, und das bei diesem schwachen Umfeld!
Weiss jemand den Grund, gab es eine Meldung?

[xpdr]

bitteschön.....
SEQUENOM Strengthens Leadership Position in Large-Scale Genotyping With Sales Of Four Additional MassARRAY(TM) SystemsSystem Purchase by Hitachi Marks SEQUENOM`s Entry Into Asian Market

SAN DIEGO, Sep 29, 2000 /PRNewswire via COMTEX/ -- SEQUENOM(TM), Inc. (Nasdaq:
SQNM), the leading provider of single nucleotide polymorphism (SNP) analysis
strategies and technology, today announced that it has sold four additional
MassARRAY systems, raising SEQUENOM`s installed commercial base of systems to
16.

Hitachi, Ltd. (NYSE: HIT), a leading global electronics company, has purchased a
MassARRAY system following the company`s recent expansion into the life science
arena. Hitachi`s Life Science Group has chosen the MassARRAY system for its
internal SNP marker validation projects while providing genotyping services to
the Japanese SNP analysis market. Hitachi established the Life Science Group
last year to promote the growth of biotechnology businesses in Japan and to
improve the health and prosperity of people around the world.

Genetics Institute, a unit of Wyeth-Ayerst and a wholly owned subsidiary of
American Home Products Corporation (NYSE: AHP), has purchased a MassARRAY system
for the high throughput quality control of oligonucleotides, short strands of
synthetic DNA used in various genomics research programs at Genetics Institute
and Wyeth-Ayerst. SEQUENOM`s MassARRAY system is the recognized gold standard
for oligonucleotide quality control.

Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC), a leader in applying
population genomics and informatics to the development of personalized
medicines, has purchased a second MassARRAY system for high-throughput SNP
analysis. The additional system purchase follows a previously announced
agreement between the two companies establishing SEQUENOM`s MassARRAY system as
the exclusive platform for Genaissance`s HAP Typing(TM) facility. The facility
was designed for the high-throughput analysis of samples from clinical trials.

Integrated DNA Technologies, Inc. (IDT), a leader in high volume oligonucleotide
production, has also purchased a second MassARRAY system from SEQUENOM. IDT has
integrated the MassARRAY technology into its high throughput oligonucleotide
synthesis platform to support its automated production and quality control. The
previously announced agreement secures a dedicated and reliable supply of
oligonucleotides, a critical factor in assay development and utilization of
genotyping technologies, for SEQUENOM and its customers.

"Hitachi, Genetics Institute, Genaissance and IDT represent four distinct
segments in genomics and we are pleased that they have each chosen our MassARRAY
system," said Toni Schuh, Ph.D., SEQUENOM`s President and CEO. "In particular,
we are pleased with the opportunity to participate in the emerging Asian
biotechnology market through our relationship with Hitachi. This marks our entry
into a market with largely untapped growth potential and symbolizes the
widespread demand for our technology.

"SEQUENOM`s technology and integrated approach to SNP analysis enable full
genome scans, which gives us a leadership position in the field," continued Dr.
Schuh. "Our unique competitive advantages include automated high-throughput
assay design, the ability to determine allele frequencies, the availability of
an in-house reference DNA bank and ultimate data quality. SEQUENOM`s customers
buy more than just genotyping technology; they buy a relationship with our
company. Our increasing number of customers demonstrates confidence in this
approach and supports our leadership position."

About Hitachi, Ltd.

Hitachi, Ltd., headquartered in Tokyo, Japan, is one of the world`s leading
global electronics companies, with fiscal 1999 (ended March 31, 2000)
consolidated sales of 8,001 billion yen ($75.5 billion*). The company
manufactures and markets a wide range of products, including computers,
semiconductors, consumer products and power and industrial equipment. For more
information on Hitachi, Ltd., please visit Hitachi`s Web site at
www.hitachi.co.jp.


*At an exchange rate of 106 yen to the dollar.

[Lailapeak]

Neue Aufträge für Sequenom
Fri Sep 29 16:49:27 2000
----------------------------------------------------------------------
Das Biotechunternehmen Sequenom (Nasdaq: SQNM) hat vier weitere Kunden für sein Massarray-System gewonnen. Dies führt zu einem deutlichen Plus des Sequenom-Papiers. Zu den Kunden gehören Hitachi (Nyse:HIT), Wyeth-Ayerst, eine Tochtergesellschaft von American Home Products (Nyse:
AHP), Genaissance Pharmaceuticals (Nasdaq: GNSC) und Integrated Technologies. Damit baut das Unternehmen die Anzahl seiner verkauften und installierten
Systeme auf 16 aus.


Besonders der Auftrag von Hitachi ist bemerkenswert. Hitachi erwirbt das Massarray-System um
seine Life-Science-Gruppe in Japan auszubauen. Das Unternehmen hat nach eigenen Angaben den Teilbereich letztes Jahr gegründet, um das
Wachstum der Biotechnologie-Industrie in Japan zu fördern. Damit wird offensichtlich, dass immer mehr HighTechunternehmen versuchen, in der Biotechnologie
Fuß zu fassen. Weitere Global-Player, die sich vermehrt in
diesem Bereich engagieren, sind Motorola und Intel.





Das Massarray-System ist in der Lage simultan Hunderte von genetischen Abschnitten zu analysieren. Dann werden sie in seiner Datenbank verglichen und untersucht sowie dauerhaft markiert. „Sequenoms Technologie und ihr
integriertes Angehen der Genanalyse ermöglichen komplette Genotype-Untersuchungen, die unserem
Unternehmen eine Führungsrolle in diesem Bereich sichern“, erläutert Präsident und CEO Toni Schuh die Vorteile von Sequenoms Technik.Der Genotype ist die Summe aller genetischen Informationen eines
Organismus.




---------------------------------------------------------------------
Autor: WallStreet-Online

[Helmut_Krumme]

Danke für die schnellen Antworten!
Das hört sich ja alles sehr gut an, lässt dies
jetzt einen länger andauernden Aufschwund erwarten?